Analysis of response rate (RR), liver resection (LR), and toxicity (T) in 129 advanced colorectal cancer (CRC) patients (pts) treated with chronomodulated infusion of ironotecan (I), 5-fluorouracil/leucovorin (F/L), and oxaliplatin (O) (CHRONO-IFLO) with or without cetuximab (Cmab).
C. Garufi
Consultant or Advisory Role - Merck Serono
Honoraria - Merck Serono
A. Torsello
No relevant relationships to disclose
I. Sperduti
No relevant relationships to disclose
V. Ferraresi
No relevant relationships to disclose
M. Zeuli
No relevant relationships to disclose
A. Gelibter
No relevant relationships to disclose
C. Campanella
No relevant relationships to disclose
M. S. Pino
No relevant relationships to disclose
C. Nuzzo
No relevant relationships to disclose
S. Tumolo
No relevant relationships to disclose
F. Cognetti
No relevant relationships to disclose